Associate Medical Director / Medical Director, Clinical Development
TempusSalary not specified
- Full Time
- Junior (1 to 2 years)
About Tempus
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.
Chicago, IllinoisHeadquarters
2015Year Founded
$894.9MTotal Funding
IPOCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
1,001-5,000Employees
Benefits
Relocation Assistance
Company Equity
Performance Bonus
Risks
Competition from partners like Genialis may lead to conflicts of interest.
Ambry Genetics acquisition could pose financial risks if synergies aren't realized.
Technical challenges may arise in integration with Flatiron's OncoEMR platform.
Differentiation
Tempus uses AI to analyze clinical and molecular data for precision medicine.
Their platform aids in personalized treatment decisions for cancer patients.
Tempus collaborates with biotech firms to enhance drug development using real-world data.
Upsides
Increased AI adoption in healthcare boosts Tempus' partnerships and collaborations.
Acquisition of Ambry Genetics expands Tempus' genetic testing capabilities.
Integration with Flatiron's OncoEMR enhances precision in cancer treatment plans.
Funding
Total raised$894.91 M
Latest valuation$6.60 B
StageIPO
IPO
5/31/2024$472
$6.60 BDEBT
9/30/2022$175
LATE VC
9/30/2022$100
$8.10 BSERIES G
11/30/2020$200
$8.10 BSERIES F
4/30/2019$200
$3.00 BSERIES E
7/31/2018$110
$2.00 BSERIES D
2/28/2018$80
$1.10 BSERIES C
8/31/2017$70
$350.00 MSERIES B
3/31/2017$30
$150.00 MSERIES A
8/31/2015$10
$50.00 M